Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- M15-990 NCT000000NA
- M15-991 NCT03105102
- M15-997 NCT03047395
- M15-998 NCT03671148
- M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No ClinicalTrials.gov identifier reported
- M15-999 NCT03875482
- M16-000 NCT03105102
- M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No ClinicalTrials.gov identifier reported
- M16-000 SKYRIZI Ph3 CD OLE Fortify NCT03105102
- M16-005 NCT03875508
- M16-006 NCT03105102
- M16-008 NCT02684370
- M16-009 No ClinicalTrials.gov identifier reported
- M16-011 NCT03675308
- M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No ClinicalTrials.gov identifier reported
- M16-011Skyrizi Ph3 PsA Keepsake 1 NCT03675308
- M16-043 NCT03069352
- M16-045 NCT03569293
- M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No ClinicalTrials.gov identifier reported
- M16-046 NCT03738397
- M16-047 NCT03568318
- M16-047 No ClinicalTrials.gov identifier reported
- M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No ClinicalTrials.gov identifier reported
- M16-048 NCT02925117
- M16-049 NCT03646604
- M16-049 - A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis No ClinicalTrials.gov identifier reported
- M16-063 NCT03682705
- M16-066 NCT03398135
- M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No ClinicalTrials.gov identifier reported
- M16-067 NCT03398135
- M16-067 NCT03398148
- M16-073 NCT000000NA
- M16-074 NCT03071757
- M16-077 NCT04295538
- M16-077 Elezanumab Ph 2a POC SCI ELASCI NCT04295538
- M16-077 - Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) No ClinicalTrials.gov identifier reported
- M16-085 NCT03567616
- M16-098 NCT03178487
- M16-100 NCT03518034
- M16-100 No ClinicalTrials.gov identifier reported
- M16-106 NCT03181126
- M16-109 NCT03222609
- M16-109 - A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No ClinicalTrials.gov identifier reported
- M16-111 NCT03924947
- M16-119 NCT03311464
- M16-123 NCT03067129
- M16-126 NCT02966795
- M16-127 NCT03069365
- M16-133 NCT03212521
- M16-135 NCT03089944